DE69504646T2 - Herstellung und stabilisierung von zellsuspensionen - Google Patents

Herstellung und stabilisierung von zellsuspensionen

Info

Publication number
DE69504646T2
DE69504646T2 DE69504646T DE69504646T DE69504646T2 DE 69504646 T2 DE69504646 T2 DE 69504646T2 DE 69504646 T DE69504646 T DE 69504646T DE 69504646 T DE69504646 T DE 69504646T DE 69504646 T2 DE69504646 T2 DE 69504646T2
Authority
DE
Germany
Prior art keywords
pct
cell suspension
solution
heavy metal
stabilization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69504646T
Other languages
English (en)
Other versions
DE69504646D1 (de
Inventor
Vivian Granger
David Barnett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sheffield Teaching Hospitals NHS Trust
Original Assignee
NORTH GEN HOSPITAL NHS TRUST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9406698A external-priority patent/GB9406698D0/en
Priority claimed from GB9413558A external-priority patent/GB2279653B/en
Application filed by NORTH GEN HOSPITAL NHS TRUST filed Critical NORTH GEN HOSPITAL NHS TRUST
Publication of DE69504646D1 publication Critical patent/DE69504646D1/de
Application granted granted Critical
Publication of DE69504646T2 publication Critical patent/DE69504646T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5002—Partitioning blood components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Processing Of Solid Wastes (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
DE69504646T 1994-04-05 1995-04-05 Herstellung und stabilisierung von zellsuspensionen Expired - Fee Related DE69504646T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9406698A GB9406698D0 (en) 1994-04-05 1994-04-05 Preparation and stabilisation of cell suspensions
GB9413558A GB2279653B (en) 1993-07-05 1994-07-05 Stabilisation of cells with an agent comprising a heavy metal compound
PCT/EP1995/001259 WO1995027203A1 (en) 1994-04-05 1995-04-05 Preparation and stabilisation of cell suspensions

Publications (2)

Publication Number Publication Date
DE69504646D1 DE69504646D1 (de) 1998-10-15
DE69504646T2 true DE69504646T2 (de) 1999-04-29

Family

ID=26304635

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69504646T Expired - Fee Related DE69504646T2 (de) 1994-04-05 1995-04-05 Herstellung und stabilisierung von zellsuspensionen

Country Status (16)

Country Link
US (1) US5858699A (de)
EP (1) EP0754301B1 (de)
JP (1) JPH10503008A (de)
CN (1) CN1149338A (de)
AT (1) ATE170979T1 (de)
AU (1) AU695573B2 (de)
BR (1) BR9507288A (de)
CA (1) CA2187196A1 (de)
DE (1) DE69504646T2 (de)
DK (1) DK0754301T3 (de)
ES (1) ES2122589T3 (de)
FI (1) FI963978A (de)
NO (1) NO964225L (de)
NZ (1) NZ284451A (de)
PL (1) PL176318B1 (de)
WO (1) WO1995027203A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2166729A1 (en) 1993-07-05 1995-01-19 Vivian Granger Preparation and stabilisation of cells
DE69504646T2 (de) * 1994-04-05 1999-04-29 North Gen Hospital Nhs Trust Herstellung und stabilisierung von zellsuspensionen
GB2313288B (en) * 1996-05-24 2000-07-12 North Gen Hospital Nhs Trust Specimen collection fluid
CA2445204C (en) * 2002-10-16 2014-08-12 Streck Laboratories, Inc. Method and device for collecting and preserving cells for analysis
CN102879317B (zh) * 2003-06-18 2016-04-13 稳定技术公司 分散相和乳化液的加速稳定性评估
US20050085028A1 (en) * 2003-10-21 2005-04-21 International Business Machines Corporation Method and structure to suppress external latch-up
CN100376669C (zh) * 2005-02-25 2008-03-26 深圳迈瑞生物医疗电子股份有限公司 生物红细胞体积长期稳定的处理方法
WO2010078194A1 (en) 2008-12-30 2010-07-08 Streck, Inc. Method for screening blood using a preservative that may be in a substantially solid state form
US11634747B2 (en) * 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
NO2398912T3 (de) 2009-02-18 2018-02-10
WO2011057184A1 (en) * 2009-11-09 2011-05-12 Streck, Inc. Stabilization of rna in and extracting from intact cells within a blood sample
US20110224495A1 (en) * 2010-03-12 2011-09-15 Tyco Healthcare Group Lp Surgical access port
CA2811349A1 (en) 2010-09-21 2012-03-29 Christian Prante Stabilized leukocytes and their use in hiv-diagnosis and therapy
WO2012151391A2 (en) 2011-05-04 2012-11-08 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
CA2917912C (en) 2013-07-24 2019-09-17 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
WO2018022991A1 (en) 2016-07-29 2018-02-01 Streck, Inc. Suspension composition for hematology analysis control
CA3050906A1 (en) 2017-01-22 2018-07-26 Chryos, Llc Composition and method of use of the same for preserving cells for analysis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1068862B (de) * 1957-05-03 1959-11-12 Penicillin-Gesellschaft Dauelsberg a Co., Göttingen Verfahren zur Verlängerung der Haltbarkeit von Blutkonserven
DE1147004B (de) * 1959-10-16 1963-04-11 Dr Med Herbert Fischer Verfahren zur Konservierung von lebenden menschlichen oder tierischen Zellpraeparaten, insbesondere von Blut und Blutbestandteilen
CA933092A (en) * 1969-04-10 1973-09-04 V. Collins Zeola Method of prolonging the viability of lymphocytes
FR2202688B1 (de) * 1972-10-17 1977-04-15 Cepbepe
US4045488A (en) * 1974-11-06 1977-08-30 Pfizer Inc. Aminophenyltetralin compounds
IT1065125B (it) * 1975-08-20 1985-02-25 Boehringer Mannheim Gmbh Processo per mantenere costante l attivita di fosfatasi alcalina e siero di controllo contenente tale fosfatasi
DE2551208C3 (de) * 1975-11-14 1981-05-27 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung einer stabilen Erythrozyten-Präparation
US4040785A (en) * 1976-10-18 1977-08-09 Technicon Instruments Corporation Lysable blood preservative composition
US4152208A (en) * 1977-03-29 1979-05-01 Hoffmann-La Roche Inc. Stabilized leucocytes
DE2828820A1 (de) * 1977-08-01 1979-02-08 Warner Lambert Co Verfahren zur herstellung einer stabilen blutplaettchensuspension und nach dem verfahren erhaltene stabile blutplaettchensuspension
US4324687A (en) * 1979-02-15 1982-04-13 Louderback Allan Lee Blood biochemistry control standard
DE2949824A1 (de) * 1979-12-12 1981-07-02 Marianne Dr. 5000 Köln Sehrbundt Verfahren zur stabilisierung von lymphozyten/thrombozytennmischsuspensionen
US4346018A (en) * 1980-06-16 1982-08-24 Coulter Electronics, Inc. Multi-purpose blood diluent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes
US4405719A (en) * 1981-05-29 1983-09-20 Coulter Electronics, Inc. Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; diluents therefor; and combination stabilization procedures
US4704352A (en) * 1985-06-25 1987-11-03 Baxter Travenol Laboratories, Inc. L-ascorbate-2-phosphate salts in blood cell storage
JPH06100606B2 (ja) * 1985-08-08 1994-12-12 リス、エ−ベルハルト 採取血中のグルコース含量の低減防止法
US4675185A (en) * 1985-12-06 1987-06-23 Baxter Travenol Laboratories, Inc. Solution for stabilizing red blood cells during storage
US4729959A (en) * 1986-02-24 1988-03-08 Streck Laboratories, Inc. Glucose reference control for glucose test strips
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
US5250438A (en) * 1990-05-09 1993-10-05 Streck Laboratories, Inc. Method for differential determination of white blood cells using diazolidinyl urea to stabilize white blood cells
SU1767436A1 (ru) * 1990-05-22 1992-10-07 Черновицкий Государственный Университет Способ определени глюкозы в крови
US5260048A (en) * 1991-05-08 1993-11-09 Streck Laboratories, Inc. Tissue fixative solution and method
US5270208A (en) * 1991-05-09 1993-12-14 Streck Laboratories, Inc. White blood cell hematology control
JPH0820452B2 (ja) * 1991-12-16 1996-03-04 株式会社いかがく 血液中糖類の微生物による消費阻止方法
US5422277A (en) * 1992-03-27 1995-06-06 Ortho Diagnostic Systems Inc. Cell fixative composition and method of staining cells without destroying the cell surface
WO1993021928A1 (en) * 1992-04-24 1993-11-11 Streck Laboratories, Inc. Liquid glucose control solution and process of making the same
CA2123227C (en) * 1992-09-10 2009-04-28 Wayne L. Ryan Method and composition for preserving antigens and process for utilizing cytological material produced by same
CA2166729A1 (en) * 1993-07-05 1995-01-19 Vivian Granger Preparation and stabilisation of cells
DE69504646T2 (de) * 1994-04-05 1999-04-29 North Gen Hospital Nhs Trust Herstellung und stabilisierung von zellsuspensionen

Also Published As

Publication number Publication date
ATE170979T1 (de) 1998-09-15
CN1149338A (zh) 1997-05-07
JPH10503008A (ja) 1998-03-17
CA2187196A1 (en) 1995-10-12
FI963978A0 (fi) 1996-10-04
EP0754301B1 (de) 1998-09-09
NZ284451A (en) 1998-03-25
PL176318B1 (pl) 1999-05-31
DE69504646D1 (de) 1998-10-15
NO964225L (no) 1996-12-05
US5858699A (en) 1999-01-12
BR9507288A (pt) 1997-09-23
PL316657A1 (en) 1997-02-03
EP0754301A1 (de) 1997-01-22
AU2305195A (en) 1995-10-23
WO1995027203A1 (en) 1995-10-12
DK0754301T3 (da) 1999-06-07
NO964225D0 (no) 1996-10-04
FI963978A (fi) 1996-12-02
AU695573B2 (en) 1998-08-13
ES2122589T3 (es) 1998-12-16

Similar Documents

Publication Publication Date Title
DE69504646D1 (de) Herstellung und stabilisierung von zellsuspensionen
BG101110A (en) Substituted pyrimidine compounds and their application
DE69428791T2 (de) Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden
PL307245A1 (en) Catalysts and their application in oxidation of saturated hydrocarbons
HK1023987A1 (en) Sulphinic acid derivatives, method for producing, and their use
NO970164L (no) Anvendelse av tiazol- og tiadiazolforbindelser som D3 - dopaminreseptorligander
DK0782567T3 (da) Isothiourinstofderivater og fremgangsmåder til deres fremstilling
DE3578063D1 (de) 1-substituierte tetralinderivate, ihre herstellung und verwendung.
ES2116371T3 (es) Aminotienopiridinas sustituidas, un procedimiento para su preparacion y su uso como medicamentos.
ES8504109A1 (es) Procedimiento de producir compuestos para el tratamiento de la hipertension
ZA200005110B (en) Process for preparing intermediates.
ATE267018T1 (de) Verwendung von peptidverbindungen zur behandlung von sle
HUT71512A (en) N-(3-chlorophenyl)-piperazine derivatives for producing alkyl-trazodon derivatives and process for producing them
BR9507623A (pt) Composto processo e precursor para á preparação do mesmo
ATE180478T1 (de) Verwendung von substituierten 6-amino-4h-pyranen
GB9410207D0 (en) Process
HU9600300D0 (en) Thiocarbamoyl derivatives using as antimicrobial agents and process for producing of these
DE68906248D1 (de) Antagonisten fuer den platelet-aktivierungsfaktor, phomactine genannt, ihre herstellung und verwendung.
ES8501397A1 (es) "procedimiento para preparar derivados de quinazolina"
MX9703846A (es) Nuevos derivados de 10, 11-dihidro-10-oxo-5h-dibenz/b, f/azepina-5-carboxamida.
UA10153A (uk) beta-[beta'-(2,4-ДІ-ТРЕТ-АМІЛФЕНОКСИ)-ЕТОКСИ] ЕТИЛХЛОРИД ЯК НАПІВПРОДУКТ ДЛЯ ОДЕРЖАННЯ РЕЧОВИН, ЯКІ МАЮТЬ АНТИМІКРОБНІ ВЛАСТИВОСТІ
SU1422601A1 (ru) Способ получения арилсульфонилизоцианатов

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SHEFFIELD TEACHING HOSPITALS NATIONAL HEALTH SERVI

8339 Ceased/non-payment of the annual fee